Bristol-Myers Squibb to Use Natera’s Cell-Free DNA Assay in Immunotherapy Study

Bristol-Myers Squibb to Use Natera’s Cell-Free DNA Assay in Immunotherapy Study

Synopsis: Bristol-Myers Squibb plans to use Natera’s circulating tumor DNA assay, Signatera, to determine whether it can successfully identify non-small cell cancer patients who might benefit from BMS’s Opdivo (nivolumab) immunotherapy.

Source: https://www.genomeweb.com/sequencing/bristol-myers-squibb-use-nateras-cell-free-dna-assay-immunotherapy-study?utm_source=Sailthru&utm_medium=email&utm_campaign=GWDN%20Thurs%20PM%20-%20Preheader%20Test%202018-09-13&utm_term=GWDN%20A/B%20Test